Prescribing informationClick here
Welcome to the healthcare professional section of Sycrest.co.uk
Sycrest (asenapine) is the first tetracyclic antipsychotic therapy for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
Sycrest is the first tetracyclic antipsychotic with a unique receptor profile:
- Sycrest demonstrates rapid efficacy as early as day 23
- Treatment response with Sycrest can be predicted early10
- Sycrest demonstrates sustained efficacy at 12 weeks 7
- Sycrest has a lower potential for long term weight gain and a lower impact on metabolic profile compared to olanzapine8